"MAP Kinase Kinase 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 44 kDa mitogen-activated protein kinase kinase with specificity for MITOGEN-ACTIVATED PROTEIN KINASE 1 and MITOGEN-ACTIVATED PROTEIN KINASE 3.
Descriptor ID |
D048370
|
MeSH Number(s) |
D08.811.913.696.620.682.700.565.200 D08.811.913.696.620.682.725.200.200 D12.644.360.440.200 D12.776.476.440.200
|
Concept/Terms |
MAP Kinase Kinase 2- MAP Kinase Kinase 2
- Kinase Activator Kinase MEK2
- MAPK-ERK Kinase 2
- MAPK ERK Kinase 2
- MAP2K2 Protein
- MAPK Extracellular Signal-Regulated Kinase 2
- MAPK Extracellular Signal Regulated Kinase 2
- Mitogen-Activated Protein Kinase Kinase 2
- Mitogen Activated Protein Kinase Kinase 2
- MEK-2 (MAPK Extracellular Signal-Regulated Kinase 2)
- MAPK Kinase 2
- MEK2 (MAPK Extracellular Signal-Regulated Kinase 2)
|
Below are MeSH descriptors whose meaning is more general than "MAP Kinase Kinase 2".
Below are MeSH descriptors whose meaning is more specific than "MAP Kinase Kinase 2".
This graph shows the total number of publications written about "MAP Kinase Kinase 2" by people in this website by year, and whether "MAP Kinase Kinase 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2000 | 0 | 1 | 1 |
2001 | 0 | 2 | 2 |
2002 | 0 | 1 | 1 |
2003 | 0 | 1 | 1 |
2006 | 0 | 2 | 2 |
2007 | 0 | 2 | 2 |
2009 | 0 | 2 | 2 |
2010 | 1 | 3 | 4 |
2011 | 0 | 2 | 2 |
2012 | 2 | 0 | 2 |
2013 | 1 | 0 | 1 |
2014 | 0 | 2 | 2 |
2015 | 1 | 1 | 2 |
2017 | 3 | 1 | 4 |
2018 | 0 | 1 | 1 |
2019 | 1 | 0 | 1 |
2020 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "MAP Kinase Kinase 2" by people in Profiles.
-
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. J Clin Oncol. 2020 11 10; 38(32):3753-3762.
-
SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy. Cancer Cell. 2020 06 08; 37(6):834-849.e13.
-
Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study. Clin Lymphoma Myeloma Leuk. 2019 07; 19(7):431-440.e13.
-
In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms. Cancer Discov. 2018 05; 8(5):568-581.
-
Prolonged Mek1/2 suppression impairs the developmental potential of embryonic stem cells. Nature. 2017 08 10; 548(7666):219-223.
-
Endometrial Cancers With Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK Inhibition. Int J Gynecol Cancer. 2017 06; 27(5):854-862.
-
Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells. Oncotarget. 2017 Feb 14; 8(7):10905-10918.
-
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. Br J Cancer. 2017 Feb 28; 116(5):575-583.
-
ERK1/2 can feedback-regulate cellular MEK1/2 levels. Cell Signal. 2015 Oct; 27(10):1939-48.
-
A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Jul; 138(1):30-5.